Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02208336 · ClinicalTrials.gov registry record
Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 79
- Enrollment target
NCT02208336 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 79 participants.
The verdict
NCT02208336 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
This research trial studies electronic medical record review in monitoring the effects of adherence on myelosuppression and morbidity in patients with newly diagnosed brain tumors receiving temozolomide and radiation therapy. Myelosuppression is a condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets and is a side effect of some cancer treatments. Morbidity is a term that refers to having a symptom of disease or medical problems caused by a treatment. Monitoring patients' electronic medical records to compare side effects, such as myelosuppression and morbidity, with treatment adherence may be a way to enhance patient care by organizing data for medical staff.
Interventions
- OTHER medical chart review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-02-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02208336
The ClinicalTrials.gov registry entry for NCT02208336 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which medical chart review is the first listed.
NCT02208336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02208336 about?
NCT02208336 is a clinical study titled "Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy". This research trial studies electronic medical record review in monitoring the effects of adherence on myelosuppression and morbidity in patients with newly diagnosed brain tumors receiving temozolomide and radiation therapy. Myelosuppression is a condition in which bone marrow activity is decreased...
What is the current status of trial NCT02208336?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2010-10. Estimated completion is 2015-02-23.
What interventions are being tested in trial NCT02208336?
The interventions under investigation include: medical chart review (OTHER).
Who is sponsoring clinical trial NCT02208336?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.